Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

CRISPR Therapeutics AG Stock Research

CRSP

45.49USD-0.57(-1.24%)Market Closed
Watchlist

Market Summary

USD45.49-0.57
Market Closed
-1.24%

CRSP Stock Price

CRSP RSI Chart

CRSP Valuation

Market Cap

3.6B

Price/Earnings (Trailing)

-4.65

Price/Sales (Trailing)

4.2K

EV/EBITDA

-7.86

Price/Free Cashflow

-9.98

CRSP Price/Sales (Trailing)

CRSP Profitability

EBT Margin

-54298.83%

Return on Equity

-47.68%

Return on Assets

-39.41%

Free Cashflow Yield

-10.02%

CRSP Fundamentals

CRSP Revenue

Revenue Y/Y

46.63%

Revenue Q/Q

-30%

CRSP Earnings

Earnings (TTM)

-776.3M

Earnings Y/Y

58.17%

Earnings Q/Q

-46.5%

Price Action

52 Week Range

38.9472.00
(Low)(High)

Last 7 days

-10.1%

Last 30 days

-9.9%

Last 90 days

-18.8%

Trailing 12 Months

-29.9%

CRSP Financial Health

Current Ratio

13

CRSP Investor Care

Shares Dilution (1Y)

2.40%

Diluted EPS (TTM)

-5.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CRSP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-30
Kulkarni Samarth
acquired
478,000
19.12
25,000
chief executive officer
2023-05-30
Kulkarni Samarth
sold
-1,621,890
64.8758
-25,000
chief executive officer
2023-05-24
Morrow Phuong Khanh
sold (taxes)
-166,555
65.91
-2,527
chief medical officer
2023-05-23
Morrow Phuong Khanh
acquired
-
-
6,938
chief medical officer
2023-04-25
Kulkarni Samarth
acquired
478,000
19.12
25,000
chief executive officer
2023-04-25
Kulkarni Samarth
sold
-1,266,640
50.6655
-25,000
chief executive officer
2023-03-29
Kulkarni Samarth
sold
-1,111,500
44.4601
-25,000
chief executive officer
2023-03-29
Kulkarni Samarth
acquired
478,000
19.12
25,000
chief executive officer
2023-03-13
Kulkarni Samarth
sold (taxes)
-408,170
43.22
-9,444
chief executive officer
2023-03-13
KASINGER JAMES R.
sold (taxes)
-99,622
43.22
-2,305
general counsel and secretary

1–10 of 50

Which funds bought or sold CRSP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
unchanged
-
666
3,425
-%
2023-09-20
BARCLAYS PLC
added
3.16
4,592,000
20,953,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
reduced
-51.29
-13,215
20,210
-%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
sold off
-100
-9,363
-
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
92,724
477,134
0.03%
2023-08-25
Gould Capital, LLC
unchanged
-
1,200
6,175
-%
2023-08-23
WOLVERINE TRADING, LLC
added
208
597,337
798,337
-%
2023-08-22
Old North State Trust, LLC
sold off
-100
-7,000
-
-%
2023-08-22
Asset Dedication, LLC
added
69.7
2,000
3,000
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
59.46
327,750
662,452
0.01%

1–10 of 44

Latest Funds Activity

Are funds buying CRSP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRSP
No. of Funds

Schedule 13G FIlings of CRISPR Therapeutics AG

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 11, 2023
ark investment management llc
10.16%
7,990,188
SC 13G/A
Feb 13, 2023
capital international investors
7.1%
5,560,492
SC 13G
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.11%
4,006,476
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
5.64%
4,319,471
SC 13G/A
Feb 11, 2022
capital international investors
4.8%
3,706,004
SC 13G/A
Feb 09, 2022
ark investment management llc
11.88%
9,087,868
SC 13G/A
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
5.64%
4,319,471
SC 13G/A
Sep 10, 2021
ark investment management llc
10.03%
7,644,350
SC 13G/A
Aug 10, 2021
capital international investors
5.6%
4,265,002
SC 13G/A
Feb 16, 2021
ark investment management llc
14.62%
10,412,976
SC 13G/A

Recent SEC filings of CRISPR Therapeutics AG

View All Filings
Date Filed Form Type Document
Sep 07, 2023
8-K
Current Report
Aug 07, 2023
S-8
Employee Benefits Plan
Aug 07, 2023
8-K
Current Report
Aug 07, 2023
10-Q
Quarterly Report

Peers (Alternatives to CRISPR Therapeutics AG)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.2B
26.6B
4.02% 19.39%
17.95
5.39
0.75% 21.34%
93.5B
27.4B
-2.63% 19.73%
17.06
3.42
-0.48% 32.56%
38.1B
10.7B
-13.40% -19.57%
31.56
3.58
-53.67% -91.41%
37.3B
10.0B
-2.69% 28.44%
13.99
3.74
-6.23% 29.40%
MID-CAP
11.1B
1.7B
5.62% 10.06%
62.93
6.64
29.01% 1345.90%
4.4B
-
-4.62% 161.21%
-7.53
48.33
54.84% -12.96%
3.0B
-
-2.68% -18.72%
-23.7
37.44
122.90% 54.78%
1.9B
80.2M
1.11% -50.65%
-5.66
23.11
42.17% -39.82%
SMALL-CAP
1.5B
121.2M
-14.37% -21.78%
-5.11
12.12
-70.36% -531.73%
989.6M
15.3M
-19.09% 6.34%
-5.45
64.63
1090.59% -36.57%
672.4M
1.6B
-20.87% -68.23%
-1.15
0.42
23.74% 60.24%
207.9M
-
-22.14% -90.61%
-0.98
1.52
116.83% 16.61%
134.5M
-
-14.96% -84.69%
-0.68
0.56
113.96% -15.19%
108.4M
2.1M
-15.22% -67.28%
-1.07
52.75
487.70% -8.66%
3.8M
-
-10.38% -96.65%
-0.05
3.21
- -129.46%

CRISPR Therapeutics AG News

MarketBeat
Valeo Financial Advisors LLC Decreases Stake in CRISPR ....
MarketBeat,
21 minutes ago
Securities.io
Seeking Alpha

Returns for CRSP

Cumulative Returns on CRSP

0.5%


5-Year Cumulative Returns

-20.0%


3-Year Cumulative Returns

Risks for CRSP

What is the probability of a big loss on CRSP?

100%


Probability that CRISPR Therapeutics AG stock will be more than 20% underwater in next one year

93.5%


Probability that CRISPR Therapeutics AG stock will be more than 30% underwater in next one year.

88.5%


Probability that CRISPR Therapeutics AG stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRSP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.

Drawdowns

Financials for CRISPR Therapeutics AG

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q22019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q2
Revenue-------914,963,0002,258,883,5003,602,804,000577,888,000--------40,997,00011,016,00010,178,000
Operating Expenses-2.7%643,739,000661,934,000674,359,000701,409,000648,600,000603,265,000541,435,000490,969,000453,843,000293,274,000242,850,000222,160,000199,390,000182,463,000162,067,000148,077,000124,039,000110,553,000105,645,000101,946,000-
  S&GA Expenses-7.5%89,562,00096,803,000102,464,000104,973,000101,681,000104,214,00099,690,000100,337,00098,167,00073,694,00063,488,00062,758,00057,414,00054,387,00048,294,00043,075,00041,012,00036,039,00035,845,00036,604,000-
  R&D Expenses-4.9%421,667,000443,335,000461,645,000461,185,000428,063,000387,172,000340,567,000273,253,000260,761,000219,580,000179,362,000159,402,000141,976,000128,076,000113,773,000105,002,00083,027,00074,514,00069,800,00065,342,000-
EBITDA100.0%--503,452,000-626,328,000-649,363,000-601,681,000337,710,000397,484,000430,027,000462,536,00027,610,00072,031,000----------
EBITDA Margin----522-2.83-0.660.370.430.510.590.051.76----------
Earnings Before Taxes19.5%-423,737,000-526,636,000-650,500,000-673,950,000-626,574,000316,510,000379,531,000415,846,000451,355,00020,612,00067,306,000-10,596,000-199,867,000-184,537,000-164,428,000-116,512,000-89,938,000-73,626,000-66,608,000-49,670,000-
EBT Margin----542-2.93-0.680.350.410.490.580.041.64----------
Net Income12.2%-776,312,000-884,406,000-650,175,000-680,848,000-633,452,000311,607,000377,661,000411,870,000446,584,00019,578,00066,858,000-11,274,000-200,408,000-185,089,000-164,981,000-117,251,000-91,247,000-75,182,000-68,357,000-51,398,000-
Net Income Margin----542-2.96-0.690.340.410.490.570.031.63----------
Free Cashflow100.0%--376,600,000-532,929,000-508,631,000-515,774,000414,365,000457,267,000465,037,000502,192,00045,333,00049,993,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.1%2,1972,2442,2432,3532,4632,6062,7522,8222,9001,9581,8281,4851,0471,0071,067721494498489519353
  Current Assets-2.5%1,8601,9081,8531,9332,1072,2612,4182,5192,6211,8321,7171,391966929988664438450466497331
    Cash Equivalents29.1%4453442124944976849231,0121,6471,1261,1691,041945890944630428438457487320
  Net PPE-1.9%15916216416616515713810675.0052.0042.0038.0034.0032.0031.0021.0020.0019.0019.0018.0018.00
Liabilities-2.2%38138936839937336135230929615216414213612112712912711897.0010288.00
  Current Liabilities-9.5%13314712115112011412096.0010083.0094.0084.0075.0055.0057.0080.0031.0028.0028.0032.0018.00
Shareholder's Equity-2.1%1,8161,8551,8751,9542,0912,2452,3992,5132,6041,8051,6641,343911886939592368380392417265
  Retained Earnings-8.6%-976-899-846-735-560-375-195-54.6772.00-686-573-466-374-294-224-255-393-339-291-243-193
  Additional Paid-In Capital1.4%2,7992,7612,7352,7092,6702,6352,5982,5662,5302,4902,2361,8081,2831,1791,162846760718682660457
Shares Outstanding0.6%79.0079.0079.0078.0078.0077.0077.0076.0076.0075.0074.0070.0061.0061.0061.0055.0053.0052.0052.0047.0047.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations2.5%-342-351-495-221-444504539544549-286-238-15355.0048.0057.0025.00-128-117-96.24-82.71-78.61
  Share Based Compensation-3.3%90.0093.0098.0052.0010310610296.0087.0074.0066.0059.0053.0049.0044.0045.0042.0039.0035.0029.0026.00
Cashflow From Investing1037.6%247-26.31-258-123-744-982-1,035-1,230-996-706-541-329-2.00-0.571.00-6.73-4.97-3.31-2.77-1.98-4.78
Cashflow From Financing19.2%40.0033.0039.0017.0038.0036.002516571,1601,2411,016908466406431125242216316318131

CRSP Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 70,000$ 158$ 170,000$ 1,098
Operating expenses:    
Research and development101,555123,223201,490241,468
General and administrative19,03226,27341,39254,294
Collaboration expense, net44,63633,92286,82864,568
Total operating expenses165,223183,418329,710360,330
Loss from operations(95,223)(183,260)(159,710)(359,232)
Other income:    
Other income, net18,4063,54431,1483,907
Total other income, net18,4063,54431,1483,907
Net loss before income taxes(76,817)(179,716)(128,562)(355,325)
Provision for income taxes(923)(6,118)(2,243)(9,726)
Net loss(77,740)(185,834)(130,805)(365,051)
Foreign currency translation adjustment28(69)60(95)
Unrealized gain (loss) on marketable securities452(3,380)6,679(15,180)
Comprehensive loss$ (77,260)$ (189,283)$ (124,066)$ (380,326)
Net loss per common share - basic$ (0.98)$ (2.4)$ (1.66)$ (4.72)
Basic weighted-average common shares outstanding79,091,06177,513,32778,885,16877,306,970
Net loss per common share - diluted$ (0.98)$ (2.4)$ (1.66)$ (4.72)
Diluted weighted-average common shares outstanding79,091,06177,513,32778,885,16877,306,970
Collaboration Revenue [Member]    
Revenue:    
Total revenue$ 70,000$ 158$ 170,000$ 336
Grant Revenue [Member]    
Revenue:    
Total revenue$ 0$ 0$ 0$ 762

CRSP Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 444,796$ 211,885
Marketable securities1,323,3071,603,433
Accounts receivable70,0000
Prepaid expenses and other current assets21,46937,708
Total current assets1,859,5721,853,026
Property and equipment, net159,172163,634
Marketable securities, non-current4,90153,130
Intangible assets, net4371
Restricted cash11,79911,635
Operating lease assets159,352156,921
Other non-current assets2,1754,640
Total assets2,197,0142,243,057
Current liabilities:  
Accounts payable27,58827,428
Accrued expenses89,83877,682
Accrued tax liabilities558135
Operating lease liabilities14,83315,842
Other current liabilities2020
Total current liabilities132,837121,107
Deferred revenue, non-current12,32312,323
Operating lease liabilities, net of current portion230,342228,179
Other non-current liabilities5,4845,969
Total liabilities380,986367,578
Commitments and contingencies, see Note 7
Shareholders’ equity:  
Common shares, CHF 0.03 par value, 79,552,682 and 78,692,766 shares issued at June 30, 2023 and December 31, 2022, respectively, 79,372,366 and 78,512,450 shares outstanding at June 30, 2023 and December 31, 2022, respectively2,4742,441
Treasury shares, at cost, 180,316 shares at June 30, 2023 and at December 31, 2022(63)(63)
Additional paid-in capital2,799,4202,734,838
Accumulated deficit(976,895)(846,090)
Accumulated other comprehensive loss(8,908)(15,647)
Total shareholders' equity1,816,0281,875,479
Total liabilities and shareholders’ equity$ 2,197,014$ 2,243,057
Samarth Kulkarni
470
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.